Search clinical trials for: CGC-11047 and erlotinib

Total 2704 results

Samsung Medical Center

Recruiting

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Biliary Tract Cancer

Korea, Republic of
Hunan Province Tumor Hospital

Recruiting

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Carcinoma, Non-Small Cell Lung | EGFR Gene Mutation

China
National Cancer Institute, Naples

Active, not recruiting

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY)

Non-squamous Non-small Cell Lung Cancer

Italy
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Carcinoma, Non-Small-Cell Lung

United States, United Kingdom
Intermountain Health Care, Inc.
Abbott

Active, not recruiting

Diabetes Discharge Transitional CGM Study (DDT-CGM) (DDT-CGM)

Diabetes Mellitus, Type 2

United States
Jing Qiao

Unknown

Concentrated Growth Factors in Regenerative Therapy in Furcation Involvements in Humans

Furcation Defects | Periodontal Regeneration | Concentrated Growth Factors

China
Eli Lilly and Company

Terminated

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States, Australia
OSI Pharmaceuticals

Terminated

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY)

Recurrent or Refractory Pediatric Ependymoma

United States, Canada, United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

EGFR-Mutant Lung Cancer

United States
SCRI Development Innovations, LLC
Genentech, Inc.

Completed

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Neoplasms, Unknown Primary
M.D. Anderson Cancer Center
Novartis; OSI Pharmaceuticals

Completed

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Head And Neck Cancer

United States
University of Utah
Bristol-Myers Squibb

Completed

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Solid Tumors

United States
Guangzhou Medical University

Completed

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Lung Adenocarcinoma | Brain Metastases

China
Nasser Hanna, M.D.
Genentech, Inc.; Hoosier Cancer Research Network; Walther Cancer Institute

Completed

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
Wenzhou Medical University

Unknown

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Esophageal Cancer

China
University of California, Davis
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cheng-Kung University Hospital

Unknown

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Non-Small Cell Lung Cancer

Taiwan
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Shanghai Chest Hospital

Recruiting

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Non-Small Cell Lung Cancer (NSCLC)

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib | Anti-PD-1 Antibody | Advanced Pancreatic Cancer

China
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
Tang-Du Hospital

Completed

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Sintilimab and Anlotinib in Combination With Chemotherapy

China
Cttq

Unknown

Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

Gastrointestinal Stromal Tumors

China
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
First Affiliated Hospital of Wenzhou Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Interstitial Lung Diseases

China
Novartis Pharmaceuticals

Completed

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Acute Lymphoblastic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML) | Metastatic Gastrointestinal Stromal Tumors (GIST) | Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Italy, United Kingdom, Canada, Singapore, Netherlands, France, Korea, Republic of, United States, Slovakia, Hungary, Russian Federation, Hong Kong, Spain, Israel, Sweden, Austria
Novartis Pharmaceuticals

Completed

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

United States, France, Korea, Republic of, Thailand, Italy, Netherlands, Turkey, Hungary, Russian Federation, Spain, United Kingdom, Japan, Malaysia
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Advanced Head, Neck and Chest Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Nanfang Hospital of Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Unresectable Stage III Non-small Cell Lung Cancer

China
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Gastrointestinal Stromal Tumors

Germany, Italy
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (MACS0911)

Philadelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic Phase

Japan
Fox Chase Cancer Center

Terminated

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) (07060)

Gastrointestinal Stromal Tumors

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Completed

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) (DREAM)

Colorectal Cancer

France, Austria, Canada
David M. Brizel, MD
Genentech, Inc.; OSI Pharmaceuticals

Completed

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Head and Neck Cancer | Pharynx Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
Tata Memorial Hospital

Active, not recruiting

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study (ERLO-XIB)

Oral Squamous Cell Carcinoma | Head and Neck Cancers | Carcinoma of Buccal Mucosa | Tongue Cancers

India
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Active, not recruiting

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

HLRCC | Sporadic Papillary Renal Cell Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States

Search clinical trials for: CGC-11047 and erlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations